Merck's undervalued stock presents growth opportunities with Keytruda and promising pipeline drugs, making it a Buy despite ...

In a move to safeguard the company’s dominant position in cancer, Merck said Thursday it will license a new cancer drug from ...

In a move to safeguard its dominant position in cancer treatments, Merck agreed to license a drug from a Chinese company ...

Germany-based BioNTech got into the space before the gold rush that was unleashed in September by the news that Akeso and ...

Eli Lilly’s Ebglyss (lebrikizumab-lbkz) showed improvement in skin clearance and itch relief for most patients with ...

But, like a surprising amount of other viruses, the coronavirus can also lead to annoying, itchy and even painful skin rashes. When you see a rash as part of a virus, you're not really seeing the ...

The UK’s medical research charity LifeArc has received a windfall of nearly $1.3 billion after selling a portion of its royalty interest in Merck & Co’s blockbuster cancer drug Keytruda to a ...

Keytruda (pembrolizumab) was cleared by the FDA as a second-line therapy for the hepatocellular carcinoma (HCC) form of liver cancer in 2018. The drug's accelerated approval looked like it could ...

This rash may come and go in flares. There's no cure for lupus, but certain medications help control symptoms. Medications can include high-dose corticosteroids or immunosuppressant drugs.

Get detailed information on Pembrolizumab, including pronunciation, uses, dosage guidelines, indications, and instructions on how and when to take it and when to avoid it. The updated prescription ...